Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03893500 · ClinicalTrials.gov registry record · NA
Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test
A NA study of Pulmonary Arterial Hypertension, sponsored by Stanford University.
- Active
- Registry status
- NA
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT03893500: Active NA study of Pulmonary Arterial Hypertension, sponsored by Stanford University.
NCT03893500 is a NA study of Pulmonary Arterial Hypertension that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 63 participants, below the 461-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03893500, a NA study of Pulmonary Arterial Hypertension, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
* Evaluate for accuracy and reproducibility of data collected via the participant-operated Walk.Talk.Track. (WTT) app combined with Apple Watch during in-clinic, technician proctored 6MWT's. * Determine whether the WTT app on the Apple Watch can accurately collect information on distance traveled and heart rate (HR) during in-clinic 6MWT run by American Thoracic Society (ATS) guidelines * Determine whether participants can operate the WTT app and Apple Watch effectively to gather accurate data in a monitored and home-based setting * Prospectively monitor for changes in WTT app recorded 6MWT results following initiation of therapy in a treatment naïve cohort of PAH participants * Evaluate whether changes from baseline in 6 minute walk distance (6MWD) and heart rate recovery at one minute (HRR1) as well as other variables that have been associated with disease severity in PAH and left-sided heart disease (resting HR, heart rate variability \[HRV\], chronotropic index \[CI\]) can be identified before the 12-week follow up when comparing the treatment arm and the control arm * Evaluate whether changes from baseline in the HRR1, resting HR, HRV and/or CI are more evident in treatment responders when compared to treatment non-responders.
Primary Outcome
Participants will be asked to walk as far as possible along a corridor for a period of six minutes.
Conditions Studied
Interventions
- DEVICE Home-based 6 minute walk test
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2025-06-30 |
| Phase | NA |
What the registry record for NCT03893500 still lists
NCT03893500 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 461-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Home-based 6 minute walk test is the first listed.
NCT03893500 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03893500 about?
NCT03893500 is a clinical study titled "Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test". * Evaluate for accuracy and reproducibility of data collected via the participant-operated Walk.Talk.Track. (WTT) app combined with Apple Watch during in-clinic, technician proctored 6MWT's. * Determine whether the WTT app on the Apple Watch can accurately collect information on distance traveled...
What is the current status of trial NCT03893500?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 63 participants. The study started on 2020-07-01. Estimated completion is 2025-06-30.
What conditions does trial NCT03893500 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT03893500?
The interventions under investigation include: Home-based 6 minute walk test (DEVICE).
Who is sponsoring clinical trial NCT03893500?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03893500 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03893500's enrollment target sits among peer trials
63 27th of 63 higher than 36 of 63 other Pulmonary Arterial Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Arterial Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
RECRUITING · NA
-
Mobile Health Intervention to Improve Exercise in Pediatric PH
RECRUITING · NA
-
A Study of Pulmonary Hypertension Peripheral Limitations
RECRUITING · NA
-
Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)
RECRUITING · NA
-
Safety and Impact of Low Resistance Exercise Training on Quality of Life in Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI